SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a sharp sell-off as a weak revenue outlook and concerns over its turnaround timeline in Greater China triggered institutional downgrades and automated selling cascades. While many community members are debating whether this marks a bottom for a long-term value play or a structural decline for a "woke" brand, others are capitalizing on the extreme oversold conditions to accumulate positions near decade-low price levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh its aggressive foundry expansion and capital structure moves against broader macroeconomic uncertainty driven by rising oil prices and geopolitical instability. The community remains deeply divided, with bulls pointing to the company's long-term manufacturing roadmap and potential for major customer announcements, while bears are focused on the stock's recent price volatility and sensitivity to regional tensions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is capturing significant attention as investors speculate on upcoming cannabis rescheduling news and federal pilot programs, with sentiment sharply divided between those betting on a short squeeze and critics pointing to the company's fiscal history and management. The stock remains a high-volatility battleground where community discussions are currently fixated on potential catalysts like shifting FDA policies and the implications of the company's upcoming earnings release.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors await the upcoming 10-K filing and earnings report, with the community closely tracking aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high among retail investors, who are actively discussing a potential valuation re-rating and the possibility of a short squeeze as the company works to resolve past narrative overhangs.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors weigh significant commercial potential from its recently approved drug, Yartemlea, against broader market pressure and aggressive short interest. The community is actively debating the stock's valuation, the impact of recent milestone payments from Novo Nordisk, and the potential for a short squeeze as traders watch for upcoming financial results and European regulatory updates.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI cloud infrastructure contract, which has triggered intense community debate over its low-float potential and possible short-squeeze dynamics. Investors are actively analyzing the company's valuation shift while discussing the impact of thin trading volume and the technical setup on the stock price.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware (RH) is experiencing extreme volatility as investors weigh the impact of ongoing tariff headwinds and a struggling housing market against the potential for a short squeeze. Market participants are heavily focused on the company's mixed earnings results and management's guidance, while the community remains sharply divided over the long-term viability of their luxury retail model in a high-interest rate environment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors debate the impact of potential memory compression technologies on future demand versus strong long-term AI-driven storage needs. The community remains deeply divided, with some traders actively shorting into the price swings while others emphasize valuation metrics and anticipate a rebound leading up to upcoming quarterly earnings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest positive Week 40 Phase 3 data, which demonstrates that sonelokimab sets a new standard in lesion control and durability for hidradenitis suppurativa. The community is actively debating the stock's significant long-term potential and clinical differentiation against incumbents, while many speculate that the upcoming institutional meetings and clinical milestones will catalyze a major repricing or buyout event.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is attracting heavy retail attention as traders speculate on a potential short squeeze, citing its history as a volatile, low-float runner and tight share structure. While the community is sharply divided between bullish expectations of a parabolic move and warnings of a pump-and-dump scheme, discussions remain intensely focused on cost-to-borrow data and the stock's tendency for rapid, high-volume spikes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened

Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - Here's Why...

SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX

SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 438.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company's stock afte...

Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. lowered its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the...

Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX

Wedge Capital Management L L P NC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,039,968 shares of the biopharmaceutical...

Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX

Wealth Enhancement Advisory Services LLC grew its position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 701.2% during the 4th quarter, according to its most recent 13F filing with the SEC...

Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are covering the stock, Marketbeat Ratings reports. Six...

Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Royalty Pharma (NASDAQ:RPRX) CFO Sells $1,584,034.23 in Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average...

Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following the sale, the chief financial officer...

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$48.38
Prev Close	$47.97
Open	$47.99
Dividend Yield	2.28%
50-Day Moving Average	$44.61
Beta	0.33
Avg. Volume	3.82M
PE Ratio	26.94

52-Week High	$47.98
52-Week Low	$29.66
Market Capitalization	$27.67B
EPS (Annual)	$1.78
Price to Book	3.17
Revenue Per Employee	$23.78M

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A